Source link : https://www.newshealth.biz/health-news/selective-role-for-single-agent-ipilimumab-after-anti-pd-1-failure-in-melanoma/
Patients with wild-type metastatic melanoma that progressed on frontline PD-1 inhibition had almost a 2-year median overall survival (OS) when treated with single-agent ipilimumab (Yervoy), a small retrospective case review showed. Median OS with post-progression ipilimumab was 23.2 months in patients with no targetable biologic markers versus 5.3 months and 4.5 months, respectively, for BRAF-mutated […]
Author : News Health
Publish date : 2024-10-08 20:59:04
Copyright for syndicated content belongs to the linked Source.
inHealth